Halaven

This page shows the latest Halaven news and features for those working in and with pharma, biotech and healthcare.

NICE set to reject wider use of Eisai’s Halaven

NICE set to reject wider use of Eisai’ s Halaven. Issues draft guidance recommending against second-line use in breast cancer. ... Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to

Latest news

NICE backs Eisai's Halaven for breast cancer

NICE backs Eisai's Halaven for breast cancer. Reverses 2012 rejection due to new data and patient access discount. ... NICE has given a green light to Eisai's third-line breast cancer therapy Halaven, reversing its 2012 rejection of the drug.
Lilly closes on first approval for sarcoma drug Lartruvo

If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved
Eisai gets green light for Lenvima in kidney cancer

Earlier this month, Eisai won EU approval for its Halaven (eribulin mesylate) product as a second-line treatment for adults with inoperable advanced liposarcoma, its second indication after metastatic breast cancer.
Oncology directions

Halaven (eribulin).
Disappointment for pharma with new Cancer Drugs Fund list

While Bayer has seen reprieve the rest were not so lucky, with Eisai's breast cancer drug Halaven (eribulin), Lilly's lung cancer therapy Alimta (pemetrexed) and Roche's blockbuster

More from news
Approximately 8 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Eisai: Bucking the trend with R&D growth

The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. “ ... Halaven's unique position as the only drug demonstrating overall survival benefit in patients who
Country report: The healthcare market in Japan

The approval of Halaven (eribulin, Eisai) for progressive breast cancer in the US in late 2010, and in Europe and Japan in early 2011, signalled the impact of a growing number

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Project / Account Manager (Medical Education): Salary TBC

Consultant Health Economics - London / Oxford: Negotiable

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Medical Writer: Great salary and benefits

Senior Account Director development role to Business Director, H...: Excellent package

Senior Systematic Review Analyst - Oxford: Negotiable

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer: Competitive Salary

Account Manager / Account Director: Competative

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Events Manager – Med Comms – Surrey: Salary TBC

Medical/ Scientific Director: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Associate Editorial Director – Med Comms – London: Salary TBC

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Production Manager – Healthcare Communications: DOE

Medical Writers: Competitive Salary and Benefits

Subscribe to our email news alerts

PMHub

Add my company

EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...